Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$3.67 – $5.61
7% from low
Exchange
OTC Link
ADRC
Borrow rate
0.25%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $612.9M | $686.3M | $629.5M | $718.7M | $718.6M | $785.7M | $854.9M | $932.2M |
| Cost of revenue | $240.0M | $274.4M | $268.9M | $297.6M | $310.7M | $331.3M | $354.6M | $389.9M |
| Gross profit | $372.8M | $411.8M | $360.6M | $421.1M | $407.9M | $454.4M | $500.2M | $542.4M |
| Gross margin | 60.8% | 60.0% | 57.3% | 58.6% | 56.8% | 57.8% | 58.5% | 58.2% |
| R&D | $29.1M | $31.3M | $26.1M | $26.9M | $29.4M | $33.4M | $35.3M | $39.7M |
| Operating income | $83.0M | $105.8M | $54.1M | $95.6M | $85.1M | $87.5M | $112.8M | $125.2M |
| EBITDA | $122.5M | $143.7M | $71.5M | $150.5M | $118.1M | $143.2M | $167.9M | $183.7M |
| Net income | $79.8M | $66.0M | $6.2M | $64.0M | $42.5M | $58.4M | $68.3M | $83.7M |
| Net margin | 13.0% | 9.6% | 1.0% | 8.9% | 5.9% | 7.4% | 8.0% | 9.0% |
| EPS (diluted) | 0.19 | 0.16 | 0.01 | 0.15 | 0.10 | 0.14 | 0.16 | 0.20 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.0B | $0.00 | $0.00–$0.00 | 0 |
| 2027 | $1.1B | $0.00 | $0.00–$0.00 | 0 |
Forward consensus · source: Financial Modeling Prep
EMBLA MEDICAL HF S/ADR
No one on the platform currently holds OSSUY.
No tracked institution reports a position in OSSUY as of their last filing.
No one on the platform has traded OSSUY yet.
| $1.9B |
| — |
| HBMHFHBM Holdings Limited | $1.56 | +0.00% | $1.3B | — |
| MEDGFMedacta Group S.A. | $83.91 | +0.00% | $1.7B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 22.5× earnings vs its 30.9× historical median P/E.
Fair value ≈ $5.25 · price $3.81 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.